European Commission launches new Biotech and Biomanufacturing Hub
Natalia Elliot | February 3, 2025 | News story | Research and Development | Biomanufacturing, Corporate, European Commission, Hub, european union
The European Commission has announced the opening of a new Biotech and Biomanufacturing Hub, supporting start-ups and small- to medium-sized enterprises (SMEs) in bringing new innovations to the EU market.
The Hub, hosted on the EU Commission’s Your Europe portal, is in all EU languages and explains such things as: the sources of EU funding available to biotech and biomanufacturing companies; the research infrastructures available to support R&D; scale-up resources, including networks, pilot and testing facilities, and market insights; intellectual property protection; authorisation processes, and; EU compliance rules and regulations.
The Hub is part of the European Commission’s Strategy, announced in March 2024, to boost biotech and biomanufacturing in the EU.
Stéphane Séjourné, executive vice president for Prosperity and Industrial Strategy at the European Commission, commented: “Biotechnology is a key driver of industrial innovation, competitiveness and productivity, while using fewer resources, producing less emissions and generating less waste. From advancing healthcare solutions to bio-based products in sectors such as chemicals, food, detergents, paper and pulp, and textiles, biotech holds transformative potential for scaling up Europe’s industrial production and increasing prosperity. The EU is set to create an optimal environment to support its scale-up, ensuring this critical sector thrives for the benefit of our citizens and industries alike. The Hub is a practical tool that will support this.”
James Spargo
3/2/25
Related Content
European Commission approves HIV prevention injection
The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first …
Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment
Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in …
Biocon Biologics gains EU approval for bone health therapies
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab …
